$MMD

MainStay MacKay DefinedTerm Municipal Opportunities Fund To Go Ex-Dividend On March 16th, 2026 With 0.065 USD Dividend Per Share

MainStay MacKay DefinedTerm Municipal Opportunities Fund (MMD.US) will trade ex-dividend on March 16th, 2026, with a cash dividend of 0.065 USD per share. Shareholders of record on this date will receive the dividend on April 1st, 2026. The article also provides definitions for cash and stock dividends.

Original reporting
富途牛牛 · Futu News
Published Jan 4, 2026, 5:09 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jan 4, 2026, 5:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
MainStay MacKay DefinedTerm Municipal Opportunities Fund To Go Ex-Dividend On March 16th, 2026 With 0.065 USD Dividend Per Share — source image
Decision brief

The 30-second read

$MMDNeutralMed
01

Why it matters

The dividend will likely cause a temporary price decline equal to the dividend amount, affecting short-term trading strategies.

02

Market read

This dividend event is relevant for traders and investors in municipal bond funds, especially those holding MMD, as it influences short-term price and income strategies.

03

What to watch

Market conditions, interest rate changes, and credit quality of the fund's holdings could influence actual price movements beyond the dividend effect.

Relevance 6/10Timing: High, as the ex-dividend date is imminent (March 16, 2026).

Background

The fund is scheduled to distribute a cash dividend, which is a common event for income-focused funds.

Company-level read

Ticker impact

$MMDNeutralHigh confidence
Context

The news pertains to the MainStay MacKay DefinedTerm Municipal Opportunities Fund, ticker MMD, which is a municipal bond fund.

Expected impact

Short-term decrease of approximately $0.065 per share on ex-dividend date, with potential recovery thereafter.

Evidence & confidence

Dividend distributions typically cause a price adjustment equivalent to the dividend amount on the ex-dividend date. Given the fixed dividend and the fund's nature, this prediction is reliable.

$MMDNeutralHigh confidence
Context

The news is directly related to the MMD fund, which may influence trading decisions for investors holding or considering this fund.

Expected impact

Expected to see a price decrease of approximately $0.065 per share on the ex-dividend date, with minimal long-term impact.

Evidence & confidence

Dividend payout events are well-understood market phenomena, and the expected price adjustment aligns with standard dividend behavior.

Market effects

Potential impact on municipal bond funds and related fixed-income sectors.

Limited, as the fund's activity is primarily within the U.S. municipal bond market.

Negligible, as this is a localized municipal bond event.

Counterpoint

Some traders might see the dividend event as an opportunity to buy the fund at a temporarily reduced price, expecting recovery post-dividend.

Key entities

  • MainStay MacKay DefinedTerm Municipal Opportunities Fund

    A municipal bond fund focusing on defined-term municipal securities.

Related articles

$REGNMed

Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)

Regeneron Pharmaceuticals reported initial trial results for ubamatamab, showing a 73% objective response rate and 11-month median progression-free survival in 11 patients with advanced low-grade serous ovarian cancer (LGSOC). The company plans to advance the drug into a Phase 3 trial and discuss the data with the FDA. LGSOC is a rare form of ovarian cancer with limited treatment options.

$HDBMed

HDFC Bank’s new CEO Anup Bagchi: From ICICI to the top job

Anup Bagchi, with over 30 years of experience in banking and financial services, has been appointed as the new MD and CEO of HDFC Bank. He previously held senior roles at ICICI Group, including CEO of ICICI Prudential Life Insurance and Executive Director at ICICI Bank. Bagchi's leadership at ICICI Bank included growing retail mortgage loans and managing operations during demonetization.

$REGNMed

Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss

Regeneron's Phase 2 COURAGE trial showed trevogrumab (anti-GDF8/anti-myostatin) preserved lean mass and muscle during semaglutide-induced weight loss in obesity patients. Results presented at EASD and in press with The Lancet. Regeneron plans a Phase 2 trial in older adults with obesity and muscle loss. Trevogrumab was well-tolerated, with common side effects including nausea and constipation.